BONEBRIDGE Bone Conduction Implant in Adults
Launched by MED-EL CORPORATION · Feb 28, 2019
Trial Information
Current as of May 07, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults, 18 years of age or older at the time of implantation
- * Conductive or mixed hearing loss, defined as:
- • Conductive hearing loss with pure-tone average (PTA) for bone conduction thresholds better than or equal to 25 dB at 500, 1000, 2000 and 3000 Hz
- • Mixed hearing loss with PTA for bone conduction thresholds better than or equal to 45dB at 500, 1000, 2000, and 3000 Hz
- • Air-bone gap greater than or equal to 30 dB at 500, 1000, 2000, and 3000 Hz
- • Ability to benefit from amplification as defined by a monosyllabic (CNC) word score of 30% correct or better
- • Bilateral BONEBRIDGE can be considered if the difference in PTA for bone conduction thresholds is 10 dB or less between the right and left ears
- • Prior experience with acoustic or bone conduction hearing aids, unless candidate is unable to wear amplification for medical reasons
- • Able to complete testing materials in English
- • CT scan indicating the patient's anatomy is adequate to enable placement of the implant
- • Ability to undergo general anesthesia
- • Appropriate motivation and expectation levels
- • Stated willingness to comply with all study procedures for the duration of the study
- Exclusion Criteria:
- • Evidence that hearing loss is retrocochlear in origin
- • Skin or scalp condition precluding use of external audio processor
- • Suspected cognitive impairment or organic brain dysfunction
About Med El Corporation
MED-EL Corporation is a leading innovator in the field of hearing solutions, dedicated to advancing the quality of life for individuals with hearing loss through cutting-edge medical devices. Established in 1989, the company specializes in the development and manufacturing of implantable hearing systems, including cochlear implants and bone conduction devices. With a strong commitment to research and clinical excellence, MED-EL actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring that patients receive the most effective treatment options. The company's mission is to break down communication barriers and empower individuals to connect with the world around them.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Columbus, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials